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Background. In 2013, the tuberculosis (TB) mortality rate was highest in southern Zimbabwe at 16%. We therefore sought to
determine factors associated with mortality among registered TB patients in this region. Methodology. This was a retrospective
record review of registered patients receiving anti-TB treatment in 2013. Results. Of 1,971 registered TB patients, 1,653 (84%) were
new cases comparedwith 314 (16%) retreatment cases.Therewere 1,538 (78%)TB/human immunodeficiency virus (HIV) coinfected
patients, of whom 1,399 (91%) were on antiretroviral therapy (ART) withmedian pre-ARTCD4 count of 133 cells/uL (IQR, 46–282).
Overall, 428 (22%) TB patients died. Factors associated with increased mortality included being ≥65 years old [adjusted relative
risk (ARR) = 2.48 (95% CI 1.35–4.55)], a retreatment TB case [ARR = 1.34 (95% CI, 1.10–1.63)], and being HIV-positive [ARR = 1.87
(95% CI, 1.44–2.42)] whilst ART initiation was protective [ARR = 0.25 (95% CI, 0.22–0.29)]. Cumulative mortality rates were 10%,
14%, and 21% at one, two, and six months, respectively, after starting TB treatment. Conclusion. There was high mortality especially
in the first two months of anti-TB treatment, with risk factors being recurrent TB and being HIV-infected, despite a high uptake of
ART.
1. Introduction
Tuberculosis remains one of the world’s biggest public health
threats and now ranks alongside HIV as the world’s leading
infectious cause of death. In 2014, there were an estimated
9.6 million people diagnosed with TB globally, of whom 1.5
million died from the disease in the same year (0.4 million
were HIV-positive). Despite this, TB incidence has slowly
declined by 18% since 2000 and it is estimated that 43
million lives were saved between 2000 and 2014 through
effective diagnosis and treatment [1]. However, given that
most deaths from TB are preventable, the death toll from the
disease is still unacceptably high and efforts to combat this
must be continuously accelerated beyond the Millennium
Development Goal (MDG) targets, in line with the recently
set Sustainable Development Goal (SDG) and the End TB
strategy targets [2]. By 2030, the ambition is to reduce TB
mortality by 90% compared with 2015. Of the 6 million new
cases of TB notified toWorld Health Organisation (WHO) in
2014, 21%were from theAfrican regionwhich had the highest
burden of TB at 281 cases per 100,000 population compared to
the global average of 133 cases per 100,000 population [1].
Zimbabwe, which is in the Southern African region, is
among the 30 high-burden TB, HIV, and MDR-TB countries
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in the world and it also has a high HIV prevalence of 15%
[3]. In 2014, Zimbabwe had an estimated TB incidence of
278 (193–379) cases per 100,000 population inclusive of HIV-
positive TB cases, whilst TB prevalence in the same year was
292 (158–465) cases per 100,000 population [1]. Furthermore,
the estimated TB mortality in 2014 stood at 50 (34–68) cases
per 100,000 population, although Zimbabwe was notably one
of the only 11 high-burden countries to meet the target of
halving the TB mortality rate by 2015 compared to 1990. The
high burden of TB in Zimbabwe is mostly associated with
HIV, with 69% of TB patients having HIV coinfection in
2014 [1]. Thus, national ART guidelines state that all TB/HIV
coinfected patients are eligible for ART and cotrimoxazole
preventive therapy (CPT) in order to improve TB treatment
success rates [4].
The TB treatment success rate for newly registered cases
in 2012 was 81% [5], which is below the 85% target rec-
ommended by WHO. According to national data, one of
the contributors to this low treatment success rate was a
high mortality rate of 8% among patients on TB treatment
regardless of type and category of TB. Further analysis of
this data showed that death rates were highest in the three
southern region provinces of Zimbabwe which are Mata-
beleland North, Matabeleland South, and Bulawayo, each
recording case fatalities of 16%, 18%, and 14%, respectively
(source: National TB Programme). Death rates in these three
provinces have been consistently high in previous years.
Given these high mortality rates, we set out to determine
among TB patients registered in the three provinces in 2013:
(i) their demographic and clinical characteristics, (ii) factors
associated with mortality, and (iii) among those who died
their time from start of anti-TB treatment to death.
2. Methods
2.1. Study Design. Thiswas a retrospective cohort study using
routinely collected data on patients receiving TB treatment.
2.2. Setting: General and Study Site. Selected for this study
were three districts from each of the three provinces with the
highest TBmortality rates in Zimbabwe in 2013 (nine districts
alltogether). Matabeleland South, Matabeleland North, and
Bulawayo provinces jointly constitute 16% of Zimbabwe’s
population according to the Zimbabwe 2012 national census
results [6] and have populations of 685,046, 743,871, and
655,675, respectively. Matabeleland South and North provin-
ces are divided into 7 rural districts. Each of these districts
has a district hospital and in some instances, there are also
mission hospitals at the second level of the health delivery
tiered system where there are medical doctors and laboratory
facilities enabling the diagnosis of TB through direct smear
microscopy and of late GeneXpert MTB/RIF.
The two provinces each have a provincial hospital where
referrals from district level are sent. Bulawayo city is Zim-
babwe’s second largest city where three of the country’s cen-
tral hospitals are located. In addition, there are a number of
polyclinics which fall under the Bulawayo City Health
Directorate and which are responsible for TB treatment in
Bulawayo city. All health facilities in the three provinces offer
general health services including TB treatment services as
part of an integrated care package.
2.3. Management of TB Cases and HIV Coinfection in Zim-
babwe. In Zimbabwe, all public health facilities offer TB
treatment services integrated with general health services.
First, all presumptive pulmonary TB cases at each health cen-
tre have their sputum collected, and sputum specimens are
sent to the nearest TB diagnosis laboratory for direct smear
microscopy or GeneXpert MTB/RIF with results expected
to return to their respective health centres within 2 days.
Patients diagnosed with TB are then entered in the health
facility DOT register and started on TB treatment. Those
with smears positive for acid-fast bacilli are diagnosed as
smear-positive PTB, whilst those with negative smears or
smears not done are referred for a chest radiograph. If the
latter is suggestive of TB, the patients may be diagnosed as
smear-negative PTB or PTB with smears not done. Extrapul-
monary TB (EPTB) is mainly diagnosed on clinical grounds
and circumstantial evidence along with supporting specific
diagnostic tests [7].
Patients are also classified and recorded by category of TB
as follows: (i) new case defined as a patient who has never
had treatment for TB or who has taken anti-TB drugs for
less than 1 month, or (ii) previously treated case defined as a
patient who has received 1 month ormore of anti-TB drugs in
the past. Patients who are previously treated for TB (named as
“retreatment cases”) are further classified by the outcome of
their most recent course of treatment either as relapse,
treatment after default, treatment after failure, transfer-in, or
retreatment others [8].
Upon starting TB treatment, patients take directly
observed treatment (DOT) using standardized anti-TB reg-
imens [8], regardless of HIV status. Monitoring is done
bacteriologically for all forms of TB since all patients on anti-
TB treatment are supposed to have their sputum tested at 2, 4,
and 5 months. Smear-negative patients who complete treat-
ment and smear-positive patients who complete treatment
with negative smears are regarded as “successfully completing
treatment.”
All presumptive TB patients are offered HIV counselling
and testing (opt-out provider-initiated) [9] and, if found to
have TB/HIV coinfection, CPT is started together with anti-
TB treatment, provided there is no contraindication. After
starting TB treatment, all HIV coinfected patients should be
referred for ART initiation and provision of HIV/AIDS care
and support within that health facility or alternatively to
the nearest ART initiating clinic within their district if ART
services are not available on site.
According to national guidelines, ART should be started
at least two weeks after the start of TB therapy that is during
the intensive phase when the patient has stabilized on anti-TB
treatment regardless of the CD4 cell count status. However,
for severely immunosuppressed patients (those with CD4 <
50 cells/uL), ART is initiated within the first two weeks of
initiating TB treatment. In 2013, ART initiation services were
found at all district, mission, and rural hospitals and selected
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primary care facilities in the three provinces although as of
2015 all health facilities are now offering ART services.
2.4. Study Population. All TB patients who were registered
in the district TB registers from the nine selected districts in
the three provinces and started on TB treatment between 1
January and 31 December 2013 were included in the study.
2.5. Data Variables, Sources of Data, and Data Collection
Procedures. Sources of data included TB and ART registers
and, in cases of missing data for ART initiation, the ART
patient files. Data were abstracted from routinely existing
health facility records into structured forms by three teams
of trained and experienced data collectors, each consisting
of 5 people. First, data were abstracted from district TB
registers for each selected district and variables collected
from these registers included TB treatment start date, patient
age and sex, TB category and type, TB treatment outcome,
other comorbidities, HIV status, pre-ART CD4 cell count,
WHO stage, and whether the patient was on ART or not.
Patient names were also collected and used to follow up
and search for missing information about pre-ART CD4 cell
count, WHO clinical staging, and ART status. These names
were used to search ART registers and individual ART care
booklets from the respective health facilities in each district
where these patients were registered and receiving anti-TB
treatment.
2.6. Statistical Analysis. Patient data collected in the struc-
tured report form was coded and single-entered by six
data entry clerks into EpiData version 3.1 (EpiData, Odense,
Denmark) and later cleaned for errors and analysed using
STATA, version 13.1 (Stata Corporation, College Station,
Texas). Proportions and their 95% confidence intervals (CIs)
were reported for categorical variables whilst medians and
interquartile ranges were reported for continuous skewed
variables. Associations between categorical variables were
determined using the chi-square test or alternatively Fisher’s
Exact test.
Univariate and multivariate-adjusted risk ratios together
with their 95% CIs and aimed at determining factors associ-
ated with mortality were calculated using generalized linear
models with a log link and binomial distribution. If there was
a convergence problem with the regression models, STATA’s
“binreg” command was implemented. Variables included in
the multivariate generalized linear models were those with
a 𝑝 value < 0.25. The multivariate generalized linear model
for HIV status, classification, and category of TB included
all study participants and were adjusted for age and level of
healthcare facility. However, separate multivariate general-
ized linear models for the variables ART use recorded, ART
initiation in relation to start of TB treatment, WHO staging,
and CD4 cell count at ART initiation whilst adjusting for
age, level of healthcare, and TB category were run separately
to avoid collinearity and were also restricted to those HIV-
positive since they did not apply to those HIV-negative.
For survival analysis, we used date of starting TB treat-
ment as time of entry and follow-up was censored at either
date of death or date last seen or date of completing TB
treatment. Time-to-event data were complete for 98% of all
individuals who successfully completed TB treatment or who
died after excluding those who were lost to follow-up, were
not evaluated, and were still on MDR-TB treatment. Whilst
those excluded should have been included in the survival
analysis as censored, this was not possible because their dates
of last DOT visit were not recorded in the TB registers.
Stratified Kaplan-Meier curves were used to graphically
assess survival proportions and calculate the median survival
time on TB treatment. A 𝑝 value < 0.05 was considered to
indicate statistical significance.
2.7. Ethical Considerations. Ethics approval was granted
locally by theMedical ResearchCouncil of Zimbabwe and the
International Union against Tuberculosis and Lung Disease
(The Union) Ethics Advisory Group, Paris, France. Privacy
and confidentiality of information drawn from the hospital
registers were ensured by excluding patient names from the
electronic data entry. All data abstracted were kept in a safe
and secure place accessible only to the investigator.
3. Results
There were 1,971 patients who were registered and started
on TB treatment between 1 January and 31 December 2013
in the selected districts of the three southern provinces.
Demographic and clinical characteristics of TB patients in
the southern region provinces are shown in Tables 1 and
2, respectively. Males constituted 1,075 (55%) of all patients
whilst the overall median age of patients was 34 years (IQR,
28–44). Close to half of all patients were receiving anti-
TB treatment at rural health clinics, whilst 436 (22%) and
341 (17%) were registered at district/provincial hospitals and
mission/rural hospitals, respectively. Only 63 (3%) of all
patients had a recorded history of travel outside Zimbabwe,
and of these 57 (90%) had been to South Africa.
Clinical characteristics of TB patients are shown in
Table 2. Of all TB patients, 1,653 (84%) were newly registered
TB patients, and of these the majority (44%) were smear-
negative pulmonary TB cases whilst 37%were smear-positive
PTB cases. Of the retreatment TB cases, 191 (62%) were
“retreatment others” whilst 78 (25%) were relapse TB cases.
Close to all patients had an HIV test result, of whom 1,538
(78%)wereHIV-positive. Of these, 1,399 (91%)were recorded
as receiving ART. More than half of all HIV-positive patients
had missing WHO clinical staging and baseline CD4 cell
counts at ART initiation. Of those with recorded WHO
clinical staging, 84% had advanced HIV disease whilst the
median CD4 cell count was 133 cells/uL (IQR, 46–282). Of
those patients with documented ART status, 584 (42%) were
on ART prior to starting TB treatment whilst 543 (39%)
initiated ART within 2 weeks of commencing TB treatment.
As shown in Figure 1, 1,419 (72%) of all TB patients
had a treatment success whilst death (22%) was the most
common adverse TB treatment outcome. Table 3 shows
relative risks and their 95% CIs for factors associated with
mortality. Patients aged 65 years and older compared to those
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Table 1: Demographic characteristics of TB patients in southern Zimbabwe, 2013.
Characteristics 𝑛 𝑁 % (95% CI)
Sex
Female 891 1,966 45.3 (43.1–47.5)
Male 1,075 1,966 54.7 (52.5–56.9)
Missing 5 1,971 0.3
Age (in years)
0–4 67 1,967 3.4 (2.7–4.3)
5–14 70 1,967 3.6 (2.8–4.5)
15–44 1,353 1,967 68.8 (66.7–70.8)
45–64 366 1,967 18.6 (16.9–20.4)
65+ 111 1,967 5.6 (4.7–6.8)
Missing 4 1,971 0.2
Median (IQR) 34 (28–44)
Type of health facility
Rural health clinic 922 1,965 46.9 (44.7–49.1)
Mission/rural hospital 341 1,965 17.4 (15.7–19.1)
Polyclinic 266 1,965 13.5 (12.1–15.1)
District/provincial hospital 436 1,965 22.2 (20.4–24.1)
Missing 6 1,971 0.3
Recorded history of travel outside Zimbabwe prior to TB treatment
Yes 63 1,971 3.2 (2.5–4.1)
No 1,908 1,971 96.8 (95.9–97.5)
IQR = interquartile range; TB = tuberculosis.
<5 years old and having retreatment TB compared to newly
treated TB were associated with higher risk of mortality
in all multivariate regression models. However accessing
treatment from a polyclinic or higher level health centre and
having CD4 count >50 cells/mL versus ≤50 cells/mL were
associated with lower risk of mortality. Being HIV-positive
was associatedwith highermortality compared to beingHIV-
negative [adjusted relative risk (ARR) = 1.87 (95% CI, 1.44–
2.42)], but among those who were HIV-positive, those on
ART had lower mortality [ARR = 0.25 (95% CI, 0.22–0.29)]
compared with those not on ART. Compared to those who
initiated ART > 3 months prior to starting TB treatment,
those who initiated ART within 2 weeks [ARR = 0.73 (95%
CI, 0.54–0.98)] were less likely to die whilst those initiated
on ART 0–3 months prior to TB treatment were more likely
to die [ARR = 1.80 (95% CI, 1.34–2.43)].
The overall mortality incidence rate was 49.1 (44.5–54.2)
per 100 person-years. Figure 2 shows the overall Kaplan-
Meier survival estimates for all patients enrolled on TB
treatment.Themortality rate increased rapidly in the first two
months of TB treatment from 10% at one month to 14% at
twomonths and eventually increased slowly over time to 21%
at the 6-month end-point. Kaplan-Meier survival estimates
for the HIV-negative compared to those HIV-positive on
ART and those HIV-positive but not documented on ART
are shown in Figure 3: 10% of the respective cohorts had
died by 13 weeks, by 7 weeks, and by less than one week,
respectively (𝑝 < 0.001). In relation to median survival time,
this could not be estimated for those HIV-negative and those
HIV-positive on ART. However, median survival time among
those HIV-positive and not on ART was 3.3 weeks (95% CI,
2.3–5.4).
4. Discussion
We conducted a retrospective review of data collected on
patients receiving anti-TB treatment in a routine programme
setting in the southern region of Zimbabwe where the TB
mortality rate is the highest in the country. This region,
where the average TB mortality rate is more than double that
of the national average of 10% [1], is a cause for concern
and attention is needed to address this huge problem. We
observed that TB coinfection with HIV among patients
on anti-TB treatment was eleven percent higher than the
national average in Zimbabwe [5]. This correlates with HIV
prevalence figures in this region which are the highest in
the country at 21%, 18%, and 19% for Matabeleland South,
Matabeleland North, and Bulawayo, respectively, compared
to the national HIV prevalence of 15.2% according to the
2010-11 Zimbabwe Demographic and Health Survey [3].
Whilst only a quarter of TB/HIV coinfected patients had a
documented CD4 cell count, we observed that these patients
presented late with low CD4 cell counts and this is similar
to previous local findings [10]. These late presentations occur
despite national guidelines recommending over the years
an increased CD4 cell count eligibility for starting ART:
from a CD4 cell count threshold of <200 cells/mL before
2010 to <350 cells/mL from 2011 to 2013 and eventually to
<500 cells/mL from 2014 onwards in accordance with WHO
guidelines [11–13]. We also observed that the elderly, those
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Table 2: Clinical characteristics of TB patients in southern Zimbabwe, 2013.
Characteristics 𝑛 𝑁 Percentage (95% CI)
TB category
New 1,653 1,969 84.0 (82.3–85.5)
Retreatment 314 1,969 15.9 (14.4–17.6)
MDR-TB 2 1,969 0.1 (0.0–0.4)
Missing data 2 1,971 0.1
Type of new TB
Smear-positive PTB 603 1,651 36.5 (34.2–38.9)
Smear-negative PTB 720 1,651 43.6 (41.2–46.0)
EPTB 227 1,651 13.7 (12.2–15.5)
Smear-not-performed PTB 101 1,651 6.1 (5.1–7.4)
Missing 2 1,653 0.12
Type of retreatment TB
Treatment after default 29 308 9.4 (6.6–13.2)
Retreatment others 191 308 62.0 (56.4–67.3)
Relapse 78 308 25.3 (20.8–30.5)
Treatment after failure 10 308 3.2 (1.7–5.9)
Missing data 6 314 1.9
HIV status
HIV-negative 419 1,971 21.3 (19.5–23.1)
HIV-positive 1,538 1,971 78.0 (76.1–79.8)
Unknown 14 1,971 0.7 (0.4–1.2)
WHO clinical staging at ART initiation∗
I 30 638 4.7 (3.3–6.7)
II 75 638 11.8 (9.5–14.5)
III 494 638 77.4 (74.0–80.5)
IV 39 638 6.1 (4.5–8.3)
Missing data 900 1,538 58.5
CD4 count (cells/mL) at ART initiation∗
≤50 96 364 26.4 (22.1–31.2)
51–200 137 364 37.6 (32.8–42.8)
201–350 74 364 20.3 (16.5–24.8)
351–500 28 364 7.7 (5.4–10.9)
>500 29 364 8.0 (5.6–11.2)
Missing data 1,174 1,538 76.3
Median (IQR) 132.5 (46; 282)
ART use recorded∗
No 139 1,538 9.0 (7.7–10.6)
Yes 1,399 1,538 91.0 (89.4–92.3)
ART initiation in relation to start of TB treatment∗
>3 months before TB treatment 412 1,399 29.4 (27.1–31.9)
0–3 months before TB treatment 172 1,399 12.3 (10.7–14.1)
<2 weeks after TB treatment 543 1,399 38.8 (36.3–41.4)
2–8 weeks after TB treatment 15 1,399 1.1 (0.6–1.8)
Not recorded 257 1,399 18.4 (16.4–20.5)
CI = confidence interval; TB = tuberculosis; MDR-TB = multidrug resistant TB; PTB = pulmonary TB; EPTB = extrapulmonary PTB; HIV = human
immunodeficiency virus; WHO =World Health Organisation; IQR = interquartile range; ART = antiretroviral therapy.
∗These variables refer only to those who were diagnosed as HIV-positive.
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Figure 1: Overall TB treatment outcomes among enrolled patient
on TB treatment in southern Zimbabwe, 2013. TB = tuberculosis.
with recurrent TB, those diagnosedHIV-positive, thoseHIV-
positive with no documentation of ART, and those HIV-
positive presenting with lower CD4 cell counts were more
likely to die during anti-TB treatment. Of particular note was
the fact that mortality was most common in the intensive
phase of anti-TB treatment particularly for those who were
HIV-positive without documented ART initiation.
A major strength of this study is that data were an
exhaustive sample of all registered cases on anti-TB treatment
in the high mortality burden districts of the three highest TB
death rate provinces, and hence this study was well powered.
Data were obtained from routinely existing programme data
which make the study representative of TB patients receiving
treatment in public health facilities in southern Zimbabwe.
Study limitations include access to few variables that may
not exhaustively provide information onmortality-associated
factors and also possibilities of incomplete recording of
important patient information such as whether an HIV-
positive patient was on ART and when they initiated ART,
dates of death, and the presence or absence of other comor-
bidities (such as diabetes mellitus) which may account for
mortality among patients who received anti-TB treatment.
Another study limitation was that there were no postmortem
facilities or access to sophisticated laboratory diagnostic
facilities and therefore the exact cause(s) of death could not
be determined.
Being HIV-positive was the most common risk factor
for mortality whilst on anti-TB treatment and this has been
reported in studies from different parts of the world such
as in Cameroon [14], the United States [15], South Africa
[16], and Ghana [17]. HIV-positive individuals with latent TB
are known to be approximately 20–30 times more likely to
develop TB disease than those who are HIV negative, at a rate
of 8–10% per year [1], because of their suppressed immune
system which can result in an increase odds of mortality
with further progression of the HIV disease killing 1 in 3
patients [18]. StartingTB treatmentwith a lowCD4 cell count,
particularly those with CD4 cell counts <50 cells/mL, was
associated with higher mortality and this is a well-established
risk factor for early mortality [19]. The declining CD4 cell
count influences both the frequency and severity of active
TB disease [20], and active TB disease may be associated
with a higher HIV viral load and more rapid progression of
HIVdisease [21]. Such cases presenting for TB treatment with
advanced HIV infection are also likely to present with other
AIDS-defining diseases which further add to the risk of dying
[22].
In this study we observed a reduction in mortality among
HIV-positive TB patients who had documented ART use
and this clearly highlights the protective effects of ART from
mortality. Similar findings by Agbor et al. [14] showed that
those who were HIV coinfected and not receiving antiretro-
viral therapy were more than twofold likely to die. Among
those HIV-infected, starting ART in the intensive phase of
TB treatment was also associated with lower mortality com-
pared to those who were previously on ART. These findings
concur with SAPiT [23], CAMELIA [24], and STRIDE [25]
clinical trials which informed WHO guidance and collec-
tively demonstrated that early initiation of ART can reduce
mortality and AIDS progression, notwithstanding the risk
of increased immune reconstitution inflammatory syndrome
(IRIS) in patients with active TB and with very low CD4
cell counts (i.e., <50 cells/mL). Those who had started TB
treatment within 3 months of ART initiation had an almost
twofold higher risk of mortality during anti-TB treatment
and this may be attributed to late presentation for ART
initiationwith advancedHIVdiseasewhich is associatedwith
“unmasking” TB-IRIS [26] and early mortality within the
first three months of ART initiation [19]. It is also possible
that there are delays in laboratory diagnosis and start of TB
treatment among presumptive TB patients identified through
intensified TB-case finding using the WHO recommended
four-symptom TB checklist within ART clinics and this
requires further investigation in future studies.
Late presentation with advanced HIV disease and low
CD4 cell counts at the time of starting anti-TB treatment
are often anecdotally reported by health workers in these
southern regions of Zimbabwe as the major reason for the
high mortality rates. Many of these patients are said to reside
as migrant workers in neighbouring South Africa where they
do not seek HIV testing and HIV treatment and care services
and commonly return to their homes to seek treatment when
they are very sick and bed-ridden. Whilst this records review
study also sought to determine the proportion of patientswho
had a history of travel to South Africa as a proxy indicator of
these HIV late presentation cases, less than five percent had
this information documented and we also did not find it to
be a significant risk factor for mortality. It is likely that this
informationmay have been underreported since TB andHIV
data collection tools are not standardized to collect this data.
Whilstmale gender has commonly been reported as a risk
factor formortality amongTBpatients in other studies [15, 16,
27], this was not the case in our study. As with other studies,
in Sub-Saharan Africa, there was higher mortality among
those with pulmonary TB for which sputum smear status
was unknown [17] and smear-negative pulmonary PTB [16].
In addition to most smear-negative PTB cases being HIV-
positive, there are potential time delays in diagnosis, after
receipt of negative sputum smears, which include undergoing
a chest radiograph (CXR) that is performed, read, and inter-
preted by a clinician and a clinical assessment. These diagno-
sis delays [28] can be associated with progression of disease
and worse treatment outcomes. Smear-not-performed PTB
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Figure 2: Overall Kaplan-Meier survival estimates among patients
on TB treatment. TB = tuberculosis.
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Figure 3: Kaplan-Meier survival estimates stratified by HIV status
and ART initiation. TB = tuberculosis; HIV = human immunode-
ficiency virus; ART = antiretroviral therapy. Note: the numbers of
HIV-negative patients and those HIV-positive on ART and not on
ART differ from those presented in Table 1 because some patients
were excluded from survival analysis because of missing outcome
status dates.
cases did not follow national guidelines which recommend
TB diagnosis with two sputum smear examinations, and this
may result in overdiagnosis of TB disease and underdiagnosis
of other respiratory diseases thus increasing mortality risk.
Mortality was also notably higher among patients with
recurrent TB [16, 27, 29] who have a strong association with
HIV infection, whether onART orwith unknownART status
[30]. Such patients are also more likely to be noncompliant
to TB treatment and hence linked with drug-resistant TB
[31]. Multidrug-resistant (MDR-TB) poses a threat to TB
control worldwide, and globally an estimated 3.5% (95% CI:
2.2–4.7%) of new cases and 20.5% (95% CI: 13.6–27.5%) of
previously treated cases haveMDR-TB. In 2013, neighbouring
South Africa was one of the countries with the highest
number of notifiedMDR-TB or Rifampicin-resistant TB (RR-
TB) cases who were eligible for MDR-TB treatment. Only
41% of those diagnosed were enrolled to treatment [5], and
this is of great concern given that Zimbabwe had the largest
number of registered immigrants in South Africa from the
Africa region in 2013 [32]. The incidence of MDR-TB is also
increasing in high human immunodeficiency virus (HIV)
prevalence settings, with high associated mortality. A recent
meta-analysis of treatment outcomes for HIV and MDR-TB
coinfected adults and children showed that treatment success
rates were low, mortality was 38% in adults (95% CI 28–
48.1) and 11.4% (95% CI 5.8–17.1) in children, and loss to
follow-up was also higher among adults (16.1%, 95% CI 9–
23.2) than among children (3.9%, 95%CI 0.9–6.9) [33]. In our
setting, it is possible thatmortality among TB patientsmay be
partly driven by undiagnosed drug-resistant TB and hence it
is important to scale up the use of Xpert MTB/RIF assays for
TB diagnosis especially in HIV settings.
Mortality was also notably higher in those aged >65 years
and this could possibly be attributed to diabetes mellitus
which is common among the elderly and causes immuno-
suppression thus increasing the risk of TB disease [34]. The
prevalence of diabetes mellitus (DM) in adults for Zim-
babwe is unexplored and therefore requires investigation.The
association between diabetes mellitus and TB has been well
documented, and some studies report that smear-negative
PTB is more common in people with diabetes, although
this association may require rigorous studies to prove an
association [35].Thismay pave theway for interventions such
as active case finding and treatment of latent TB and efforts to
diagnose, detect, and treat DM may have a beneficial impact
on TB control. It is also possible that rifampicin-, isoniazid-,
and pyrazinamide-containing regimens led to anti-TB drug-
induced liver disease in these elderly patients [36], and this
in turn can lead to drug-induced acute liver failure which
is associated with high mortality [37]. This also will require
further exploration in future studies.
There are a number of programmatic implications from
this study. First it is important to continue doing HIV
testing for all presumptive TB patients given the high HIV
coinfection in these settings and subsequently ensuring that
all TB patients who are HIV-infected are started on ART as
soon as possible after anti-TB treatment. Second, with most
clinicalmanagement and initiation onART andTB treatment
being done by nurses, it is important to ensure that there is
continued clinical mentorship and training of these cadres
to manage any arising drug interactions in the treatment of
HIV-associated TB or TB-related IRIS given the complexities
of patients presenting for TB treatment with advanced HIV
disease. Third, it is necessary to scale up the use of the Xpert
MTB/RIF assay technology to diagnose TB among HIV-
infected patients in order to identify drug-resistant TB so that
these patients receive appropriate treatment. This will reduce
reliance on the use of sputum smear microscopy which is
also less sensitive among HIV-infected TB patients with low
CD4 cell counts. Finally, it may be worthwhile exploring the
burden of DM among TB patients, particularly among the
10 Tuberculosis Research and Treatment
elderly who are at higher risk of noncommunicable diseases,
in order to enable appropriate management.
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